Business
4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast
24-week landmark safety and clinical activity data for 45 patients enrolled in the Population Extension cohort expected to be presented (N=30 at 3E10
About this update from 4d Molecular Therapeutics, Inc.
[{"type":"text","content":"24-week landmark safety and clinical activity data for 45 patients enrolled in the Population Extension cohort expected to be presented (N=30 at 3E10 vg/eye)Clinical data will be presented by Raj K. Maturi, M.D., a Principal Investigator in the PRISM study, at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting on July 17, 2024 at 8:49 a.m. CESTCompany to provide a high-level safety update on 4D-150 treated patients from PRISM and SPECTRA studies (N=139) Company to host webcast on Wednesday, July 17, 2024 at 6:30 a.m. ET EMERYVILLE, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that the Company will present the initial interim 24-week landmark analysis from the Population Extension cohort of the PRISM Phase 2 Clinical Trial evaluating 4D-150 in a broad wet AMD patient population at the ASRS Annual Scientific Meeting being held in Stockholm, Sweden from July 17-20, 2024. The Company will host a webcast to discuss the data in detail on Wednesday, July 17 at 6:30 a.m. ET. Arshad M. Khanani, M.D., M.A., FASRS, the lead Principal Investigator in the PRISM clinical trial, will also present on the webcast and be available for Q&A. ASRS Annual Scientific Meeting Presentation Details Title:Phase 2 Population Extension Cohort in the PRISM Trial Evaluating 4D-150 in Adults with Neovascular Age-related Macular DegenerationSession:Wet AMD Symposium 1Date/Time:Wednesday, July 17, 2024 (8:49-8:53 a.m. CEST)Presenter:Raj K. Maturi, M.D., Midwest Eye Institute & Retina Partners Midwest, Indianapolis, IN The presentation will also be available on the 4DMT website: https://4dmoleculartherapeutics.com/pipeline/#posters-and-publications Corporate Webcast Details Title:4D-150 Initial Interim 24-week Landmark Analysis from PRISM Phase 2 Population Extension Cohort in Broad Wet AMDDate/Time:Wednesday, July 17, 2024 at 6:30 a.m. ETRegistration:Link An archived copy of the webcast will be available for up to one year by visiting the “Investors & Media” section of the 4DMT website: https://ir.4dmoleculartherapeutics.com/events. About 4DMT 4DMT is a leading clinical-stage genetic medicines company focused on unlocking...